The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2024 | Transforming therapy for patients with relapsed myeloma: the era of bispecific antibodies
Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, discusses the transformative impact of bispecific antibodies in relapsed/refractory multiple myeloma (R/R MM). Prof. Mohty highlights that bispecific antibodies, particularly those targeting BCMA and GPRC5D, offer a promising treatment modality, especially for patients who cannot access or tolerate CAR T-cell therapies. He emphasizes the need for careful management of opportunistic infections and ongoing evaluation of optimal treatment duration. This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
